Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006087 | 1.00 | KDM4E (0.45) | KDM4EAPEX1BLMTSHRPOLB | |
| SCHEMBL5255963 | 1.00 | KDM4E (0.45) | KDM4EAPEX1BLMTSHRPOLB | |
| SCHEMBL1007468 | 0.88 | ALDH1A1 (0.45) | KDM4EAPEX1BLMTSHRPOLB | |
| SCHEMBL1006533 | 0.88 | ALDH1A1 (0.45) | KDM4EAPEX1BLMTSHRPOLB | |
| SCHEMBL1007466 | 0.88 | ALDH1A1 (0.45) | KDM4EAPEX1BLMTSHRPOLB | |
| SCHEMBL1010044 | 0.87 | KDM4E (0.54) | KDM4EAPEX1BLMTSHRPOLB | |
| Hydrochloric Acid SCHEMBL14311866 | 0.85 | KDM4E (0.52) | KDM4EAPEX1BLMTSHRPOLB | |
| SCHEMBL16051184 | 0.82 | — | — | |
| SCHEMBL167637 | 0.81 | HSD17B10 (0.42) | PDCD1CD274OPRM1OPRD1OPRK1 | |
| SCHEMBL873557 | 0.81 | HSD17B10 (0.42) | PDCD1CD274OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958910-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | Domainex Limited (GB) | 2015-12-30 | — | — | EP | claimed |
| WO-2014128486-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2014-08-28 | — | — | WO | claimed |
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2011-05-05 | — | — | US | claimed |
| EP-2268616-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | Chlorion Pharma, Inc. (CA) | 2011-01-05 | — | — | EP | claimed |
| WO-2009114950-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2009-09-24 | — | — | WO | claimed |
| US-10336761-B2 | TGFβ receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336761-B2 | TGFβ receptor antagonist | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| EP-3325484-A1 | TGF BETA RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017015425-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015425-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2011-05-05 | — | — | US | disclosed |
| EP-2268616-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | Chlorion Pharma, Inc. (CA) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009114950-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009114950-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | CHLORION PHARMA, INC. (CA) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336761-B2 | TGFβ receptor antagonist | TGFBR2, TGFBR1, SMAD2 | KDM4E 2426/4885APEX1 3002/4885BLM 3041/4885 |
| US-20180215761-A1 | TGF BETA RECEPTOR ANTAGONISTS | TGFBR2, TGFBR1, TGFB2 | KDM4E 2682/4885APEX1 3715/4885BLM 3472/4885 |
| US-20110105488-A1 | SUBSTITUTED PYRROLIDINE AND PIPERIDINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS FOR TREATING PAIN | PAM, PNN, NOD1 | KDM4E 1799/4885APEX1 2524/4885BLM 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.